This study presents the synthesis, characterization, and antitumor action of five new Pt(II) halogenido, chlorido, and iodido complexes with edda type of ligands. (S,S)- 
| INTRODUCTION
Blood cancers (leukemia, lymphoma, myeloma, and myelodysplastic syndromes) account for 10.2% of new malignancies diagnosed in the USA in 2016. [1] Survival rates vary by leukemia subtype, and average 5-year survival is <30% for patients with acute myeloid leukemia. As chemotherapy is used to treat most types of leukemia, the search for new and more effective drugs is ongoing. The discovery of the potent antitumor activity of cisplatin was the beginning of platinum-based medicinal chemistry. [2, 3] Cisplatin binds at the N7 position of guanine and by forming a range of adducts, intrastrand in particular, causes DNA damage and provokes apoptosis. [4] Apoptosis, a type of regulated programmed cell death, [5] is a mechanism of action of many chemotherapeutics. Apoptotic cells undergo caspase activation (through extrinsic or intrinsic pathways), phosphatidylserine externalization on the outer leaflet of the cell membrane, and DNA and cytoplasm fragmentation in the absence of plasma membrane damage. They are quickly engulfed by phagocytic cells in the absence of immune response. [6] Nowadays, cisplatin is used in the therapy of lymphomas and myelomas, testicular and ovarian cancer, bladder, melanoma, non-small-cell, and small-cell lung cancer. [7] However, † These authors equally contributed to the work.
it is not universally effective in all cancer types and causes a number of side-effects. [8] In the last four decades, scientists have been searching for novel analogues of cisplatin in order to overcome its toxicity and tumor resistance. Initially, new platinum antitumor agents had two cis non-leaving amino ligands and two cis good leaving groups in their structure. Amino ligands were monodentate or bidentate amines, while the most common leaving groups were chlorido or carboxylato ligands. Only two of thousands of synthesized and tested platinum compounds have been introduced into clinical use: oxaliplatin and carboplatin [9] [10] [11] [12] (Figure 1 ). Carboplatin and oxaliplatin are thought to possess mechanism of action similar to that of cisplatin, which is in essence DNA damage induction. Carboplatin causes fewer side-effects compared with cisplatin, while oxaliplatin shows improved performance toward colorectal cancers. Nevertheless, cisplatin still remains the chemotherapeutic agent of choice in a number of malignancies. [13, 14] Among numerous complexes investigated so far, diamminedichloridoplatinum(II) complexes are of special importance. A series of asymmetric platinum complexes cis-Pt(LL′)Cl 2 (L=NH 3 , L′=CH 3 NH 2 , (CH 3 ) 2 NH, C 2 H 5 NH 2 , and (C 2 H 5 ) 2 NH and LL′=N,N-dimethylethylenediamine) were synthesized and tested in mouse lymphocytic leukemia cells, demonstrating IC 50 values almost comparable to those of cisplatin. [15] Furthermore, with the aim of increasing lipophilicity, diaminocyclohexane platinum complexes were synthesized and their in vitro antitumor activity was widely studied. For example, water-soluble square-planar hydroxylated 1,2-diaminocyclohexane platinum(II) complex possesses the property of inhibiting the growth of tumors in mammals. [16] Another class of diamine platinum(II) compounds with antitumor activity is a group of ethylenediamine-based platinum complexes. In the last decade, a number of these complexes were synthesized, using chelating ethylenediamine ligands derived from different amino acids and 1,2-dibromethane, [17] including Pt(IV) and Pt(II) complexes with ethylenediamine-N,N′-diacetate (edda)-type ligands. These complexes showed antitumor activity equal to or better than cisplatin on a wide spectrum of tumor cell lines. [18] [19] [20] The possibility to replace chlorides with iodides within biologically active square-planar platinum(II) complexes has been recently described. [21, 22] Namely, Pt-Cl bond more easily hydrolyzes than corresponding Pt-I bond, contributing to higher reactivity and biological efficacy compared with diiodidodiaminplatinum(II) complexes. The first report on cis-[PtI 2 (NH 3 ) 2 ] documented the lack of antitumor activity in chosen in vivo animal models. [23] Nonetheless, several recent studies highlight an unexpected reactivity of iodido Pt(II) and Pt(IV) complexes toward serum albumin and glutathione. [24] [25] [26] Our recent paper describes the synthesis and antitumor activity of three new platinum(II) iodido complexes with cyclohexyl-substituted ethylenediamine-type ligands. [27] The report shows that these complexes have a good in vitro antitumor activity, comparable with cisplatin. It has also been stated that bulky ligands increase lipophilicity with iodide ligands enabling kinetic stability in physiological conditions, thus leading to better intracellular accumulation and DNA binding, compared with cisplatin. [27] Bearing in mind that cisplatin is still a widely used antitumor agent and that its analogue carboplatin together with other chemotherapeutics is included in phase II trial of relapsed/refractory Hodgkin lymphoma, [28] 
propanoic acid dihydrochloride and its methyl, ethyl, and n-propyl esters were prepared according to the previously described procedure. [20] K 2 [PtCl 4 ] was prepared by the well-known reduction of the K 2 [PtCl 6 ] with hydrazine. [29] Solvents were obtained commercially and used without further purification.
(S,S)-Ethylenediamine-N,N′-di-2-(3-cyclohexyl)propanoic acid dihydrochloride and its methyl, ethyl, and n-propyl esters, used for the synthesis of complexes described below, were prepared according to the procedure described in the literature [20] and were marked as L 2 , L 3 , L 4 , in the same manner as in our previous work. According to this, previously synthesized complex Pt(IV) with ligand L 3 is designated as C3 in this study. C presented in deuterated dimethylsulfoxide (DMSO). Melting points were determined on electrothermal melting point apparatus.
Agilent 6210 Time-of-Flight LC/MS system (Agilent Technologies, Santa Clara, California, USA) equipped with an ESI interface (ESI-TOF-MS) was used for the identification of compounds. The ESI was operated in a positive mode and nitrogen was used as the drying gas (12 L/min) and nebulizing gas at 350°C (45 psi). The OCT RF voltage was set to 250 V and the capillary voltage was set to 4.0 kV. The voltages applied to the fragmentor and skimmer were 140 and 60 V, respectively. Scanning was performed from 100 to 2,000 m/z (mass-to-charge ratio). The compound identification was as follows: The compound was dissolved in the methanol (concentration of 1 mg/ml), and a direct injection of 0.01 μl sample was conducted by 1,200 Series HPLC (Agilent Technologies, Waldbronn, Germany) without a separation column. The isocratic mobile phase consisted of 50% acetonitrile and 50% of 0.2% formic acid in water (v/v) at a flow rate of 0.2 ml/min. 
| Synthesis of [PtCl 2 (L 3 )], C3a
The complex was synthesized as described for complex C2a using 119.28 mg (0.24 mmol) of L 3 . The compound was isolated as yellow powder.
Yield: 0.086 g, 51.93%. Mp. 168°C. FTIR (ATR): 
| Synthesis of [PtI 2 (L 3 )], C3b
The complex was synthesized as described for complex C2b using 119. 
| Synthesis of [PtI 2 (L 4 )], C4b
The complex was synthesized as described for complex 
| Cell viability
The acid phosphatase and the lactate dehydrogenase (LDH) assays were used to measure the number of viable cells. The acid phosphatase assay is based on p-nitrophenyl phosphate hydrolysis by intracellular acid phosphatases in viable cells and subsequent production of p-nitrophenol. In brief, p-nitrophenyl phosphate solution (for HL-60 and REH: 55 mg p-nitrophenyl phosphate, 5 ml of 0.3 M sodium acetate buffer, pH 5.5, with 0.3% Triton X-100; for U251 and H460: 37.4 mg p-nitrophenyl phosphate, 7 ml of 0.1 M sodium acetate buffer, pH 5.5, with 0.1% Triton X-100) was added to each well and the samples were incubated for 2 hr at 37°C. The reaction was stopped by addition of 50 μl of NaOH (1.3 M for HL-60 and REH and 1 M for U251 and H460) and the absorbance, which is directly proportional to the cell number, was measured in an automated microplate reader (Sunrise; Tecan, Dorset, UK) at 405 nm. The results were presented as % absorbance relative to untreated control. The IC 50 values were calculated using GRaphpaD pRISM software.
The release of cytosolic enzyme LDH reflects a loss of membrane integrity and therefore necrotic type of cell death. The test was performed exactly as previously described. [30] The results were calculated using formula:
where E is the experimental absorbance of treated cells, C is the control absorbance of untreated cells, and T is the absorbance of Triton X-100-lysed cells. The results were presented as a percentage (%) of viable cells.
| Flow cytometric analysis of ROS production and apoptotic parameters
The flow cytometry analysis was performed using CellQuest Pro software for acquisition and analysis on a FACSCalibur flow cytometer (BD Biosciences, Heidelberg, Germany).
Production of reactive oxygen species (ROS) was determined by measuring the intensity of green fluorescence emitted by a non-selective redox-sensitive dye dihydrorhodamine 123 (DHR; Invitrogen, Paisley, UK), which was added to cell cultures (5 μM) at the beginning of treatment. After incubation, cells were washed in PBS and the increase in green fluorescence (FL1) was analyzed as a measure of ROS production. Mitochondrial production of superoxide ions was analyzed using flow cytometry by measuring the intensity of red fluorescence (FL2) emitted by a superoxide-specific fluorochrome dihydroethidium, DHE (Sigma-Aldrich), which was incubated with cells (20 μM) for 30 min at the end of
the treatment. The type of cell death (apoptotic or necrotic) was analyzed by double staining with annexin V-fluorescein isothiocyanate (FITC), which binds to early apoptotic cells with exposed phosphatidylserine, and propidium iodide (PI), which labels the late apoptotic/necrotic cells with membrane damage (staining kit from BD Pharmingen, San Diego, CA, USA). The annexin-negative (Ann − )/PI + cells were considered necrotic. DNA fragmentation was assessed by the flow cytometric analysis of ethanol-fixed cells stained with DNA-binding red fluorescent (FL2 channel) dye propidium iodide (PI). The hypodiploid cells (sub-G 0 compartment) were considered apoptotic.
The activation of caspases was assessed using flow cytometer by measuring the increase in green fluorescence (FL1) of the cells stained with FITC-conjugated: pan-caspase (ApoStat; R&D Systems); caspase 8 (CaspGLOW Fluorescein Active Caspase-8 Staining Kit), caspase 9 (CaspGLOW Fluorescein Active Caspase-9 Staining Kit), and caspase 3 (CaspGLOW Fluorescein Active Caspase-3 Staining Kit) inhibitors, all from BioVision, Inc, Milpitas, California, exactly according to the manufacturer's instructions.
The acidic autophagolysosomes were detected by the flow cytometric analysis of the cells stained with pH-sensitive supravital dye acridine orange which stains cytoplasmic autophagolysosomes orange-red, while nuclei green. Therefore, if present, autophagy is detected as an increase in red/green fluorescence ratio (FL3/FL1). After incubation, the cells were washed with PBS and stained with acridine orange (1 μM) for 15 min at 37°C. Cells were then washed in PBS and analyzed on the flow cytometer.
| Statistical analysis
Statistical analyses were performed using Student's t test for small independent samples. A p value of <0.05 (p < .05) was considered significant. 
| Spectroscopic studies
In the IR spectra of all synthesized complexes, characteristic C=O stretching bands appear at 1,740-1,745 cm −1 . There are no significant changes in the values for these vibrations compared with free ligands, [20] indicating non-involvement of these groups into co-ordination. 
| Antitumor activity studies
Acid phosphatase assays demonstrated that both ligands and corresponding novel chlorido and iodido Pt(II) complexes reduced the number of viable cells in most of investigated tumor cell lines. Novel complexes had superior antitumor action compared with their organic ligands, with iodido being more efficient than chlorido complexes of the same type. With the exception of C2a, the efficacy of complexes was equal to or superior than cisplatin in 24-hr antitumor action. In this respect, C3b was the most powerful with IC 50 value of approximately 3 μM on all tested tumor cell lines. Furthermore, the antileukemic action of C3a was four times stronger than its previously reported Pt(IV) complex analogue C3, [20] or cisplatin ( Table 1) .
previously reported, with L 3 marked as the most potent ligand and the HL-60 cell line as the most sensitive to its cytotoxic action. [31] In the present study, human promyelocytic cell line (HL-60) was also the most sensitive to antitumor action of all investigated substances. Accordingly, we were particularly interested in determining the mode of antileukemic action of novel C3a and C3b complexes. Furthermore, antitumor action of Pt(IV) chlorido complexes corresponding to herein investigated Pt(II) revealed good antiglioma action [20] but antileukemic action remained unexplored. Thus our goal was to examine the antileukemic potential of C3, chlorido Pt(IV) complex analogue, and compare it to chalogenido Pt(II) complexes (C3a and C3b).
| ROS production and induction of oxidative stress
Having in mind that oxidative stress was the initial event involved in antileukemic action of organic ligand L 3 , [31] we first analyzed the ability of novel Pt(II) complexes to increase production of ROS and cause oxidative stress in HL-60 cells.
Obtained results show that 4-hr treatment with both novel complexes, C3a and C3b, as well as Pt(IV) analogue C3, induced ROS production (when applied in IC 50 concentrations) (Figure 2 ), unlike cisplatin and organic ligand L 3 , in the same experimental setting (data not presented for clarity). Namely, both C3a (5 μM) and C3b (3 μM) induced ROS hyperproduction with C3b being more potent, causing twofold increase in ROS-mediated DHR-derived fluorescence intensity (FL1) in comparison with untreated control (Figure 2a) . Furthermore, C3a also caused ( Figure 2b ) the increase in DHE-derived fluorescence intensity (FL2), suggesting the superoxide hyperproduction indicative of oxidative stress. The treatment with C3 complex (4 hr, 18 μM) caused more pronounced increase in DHR-derived FL1 fluorescence compared with novel complexes (Figure 2a) , suggesting that C3, despite the lack of noticeable increase in superoxide production (Figure 2b ), induces rapid and prominent oxidative damage in HL-60 cells, as observed previously in U251 glioma cells. [20] On the other hand, it was shown that organic ligand induced mitochondriaderived superoxide hyperproduction in HL-60 cells, [31] unlike cisplatin, [20] indicating that cyclohexyl-functionalized edda ligands significantly contributed to mitochondria-derived oxidative damage.
| Investigation of cell death type
We next investigated the type of leukemic cell death induced by treatment with representative novel Pt(II) complexes (C3a, C3b) and their Pt(IV) complex analogue (C3). The LDH test indicated that 24-hr treatment with C3a (24 hr, 5 μM) and C3b (24 hr, 3 μM) resulted in less cell membrane damage than treatment with C3 (24 hr; 18 μM), suggesting that for novel Pt(II) complexes, necrosis is not as relevant a mechanism of cell death as for Pt(IV) complex (Figure 3a ). This result is in accordance with the result obtained for C3 on U251 glioma cells. [20] In order to determine the exact apoptotic pathway, we investigated the activity of initiator caspases 8 and 9 and executioner caspase 3 in HL-60 cells after treatment. Novel complexes C3a and C3b both induced marked caspase 8 activation after 2 hr, that decreased at later time-points (6 and 12 hr) (Figure 3b ). Complex C3 also caused caspase 8 activation, but to a lesser extent compared with novel Pt(II) halogenido complexes. Unlike caspase 8, the increase in caspase 9 activity with novel Pt(II) halogenido complexes was moderate (1.7-fold after 2 hr treatment) and also decreased during the time, whereas with C3 caspase 9 activation was not detected (data not shown). Caspase 3 activation was more pronounced following novel Pt(II) halogenido complexes' treatment (12 hr), compared with the C3 treatment (Figure 3c ). Pan-caspase activation was still present in HL-60 cells after 24-hr treatment with C3a, C3b, and C3 (Figure 3d ). Our data show that novel Pt(II) halogenido complexes induce activation of both caspases 8 and 9, the former twice more pronounced than the latter. Although mixed (extrinsic-intrinsic) apoptotic HL-60 cell death has been described as a cytotoxic mechanism of action for some plant extracts and their chemical constituents, [32] and taking into account a possible overlap in specificity of caspase inhibitors used, [33] our data speak in favor of dominant role of caspase 8 activation in induction of leukemic cell death. The lack of caspase 9 activation by Pt(IV) analogue C3 implicates the major role of extrinsic apoptotic pathway. Additionally, both novel complexes, C3a (5 μM) and C3b (3 μM), later (24 hr) (Figure 3c) . Furthermore, 24-hr treatment of HL-60 cells with C3a (5 μM) and C3b (3 μM) caused massive disturbance in HL-60 cell cycle distribution with cell accumulation in sub-G 0 phase (>40%) indicating DNA fragmentation (data not shown). The intrinsic AIF-mediated leukemic cell death has been reported as organic L 3 ligand mechanism of action. [31] The obtained results demonstrated that Pt(II) complexes investigated herein induce apoptotic cell death of leukemic cells in the concentration several times lower compared with organic ligands. This indicates that complexation with platinum improves the antileukemic effect and possibly contributes to the extrinsic apoptotic pathway induction. On the other hand, Pt(IV) complexation results in the presence of both apoptotic and necrotic markers of leukemic cell death, but in higher concentrations in comparison with Pt(II) complexes. Having in mind that Pt(IV) complexes are reduced to Pt(II) complexes in bloodstream [34, 35] in order to achieve their biologically active form, Pt(II) complexation with this type of organic ligands might be a better option for achieving antileukemic effect. It is noteworthy that the treatment with C3a (5 μM), C3b (3 μM), and C3 (18 μM) failed to cause any increase in acidic cytoplasmic content in HL-60 cells (data not shown), implying the lack of autophagy involvement in novel Pt(II) complexes' antileukemic action and confirming the result obtained on U251 glioma cells treated with C3. [20] 4 | CONCLUSION Herein we present the synthesis of new cisplatin analogues, dihalogenido Pt(II) complexes with cyclohexyl-substituted ethylenediamine-type ligands and report better antitumor efficacy of iodido than corresponding chlorido complexes. The novel Pt(II) complexes, excluding C2a, exhibited comparable or better antitumor action in comparison with cisplatin and superior to precursor ligands. Human promyelocytic cell line (HL-60) was allocated as the most sensitive to cytotoxic action of all investigated substances, and was used for investigation of the underlying mode of antileukemic action. The investigated novel Pt(II) complexes C3a and C3b showed more potent antileukemic action than corresponding Pt(IV) complex C3, through induction of oxidative stress and apoptosis, evidenced by caspase activation and phosphatidylserine externalization. Obtained results indicate that novel Pt(II) halogenido complexes with cyclohexyl edda-type ligands could have better antileukemic potential than corresponding Pt(IV) complexes and warrant further research.
